

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. XANO/33	SERIAL NO. 10/681,431		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Keith Moore			
(37 CFR 1.98(b))				FILING DATE October 8, 2003	GROUP 1714		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
UR	AL	06121698	06-05-94	Japan	C12Q	1/68	Abstract only
	AM						
	AN						
	AO						
	AP						
	AQ						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
UR	AR	Dahl, Svein G., <u>Pharmacokinetics of methotrimeprazine after single and multiple doses</u> , Clinical Pharmacology and Therapeutics, 1976; 19:435-442					
UR	AS	Dahl, Svein G., <u>Active Metabolites of Neuroleptic Drugs: Possible Contribution to Therapeutic and Toxic Effects</u> , Therapeutic Drug Monitoring, 1982; 1:33-40					
UR	AT	Dahl, Svein G, et al., <u>Plasma and Erythrocyte Levels of Methotrimeprazine and Two of its Nonpolar Metabolites in Psychiatric Patients</u> , Therapeutic Drug Monitoring, 1982; 4:81-87					
EXAMINER Chaf Green				DATE CONSIDERED 8/24/2006			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							